bioMérieux S.A. (EPA: BIM)

Market Cap	12.37B
Revenue (ttm)	3.67B
Net Income (ttm)	357.60M
Shares Out	118.16M
EPS (ttm)	3.01
PE Ratio	34.78
Forward PE	25.53
Dividend	0.85 (0.81%)
Ex-Dividend Date	Jun 7, 2024

Volume	168,971
Open	105.00
Previous Close	105.10
Day's Range	104.50 - 105.70
52-Week Range	84.54 - 108.90
Beta	0.19
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 5, 2024

About bioMérieux

bioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems that use biological samples, such as blood, saliva, urine, etc. for the diagnosis of infectious diseases, including bacterial infections, parasitic infections, and viral infections; and microbiological control of production or the production environment primarily for food, pharmaceutical, and cosmetic industries. It also provides a suite of...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1963
• Employees: 13,982
• Stock Exchange: Euronext Paris
• Ticker Symbol: BIM

Financial Performance

In 2023, Bureau Veritas's revenue was 5.87 billion, an increase of 3.84% compared to the previous year's 5.65 billion. Earnings were 503.70 million, an increase of 7.93%.